- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01765322
The Effect of Laser-assisted Zona Thinning on the Implantation Rate in the Women of Advanced Age
November 25, 2013 updated by: Shi Wenhao, Shanxi Provincial Maternity and Children's Hospital
Center of Assisted Reproductive Technology
The purpose of this study is to determine whether laser-assisted zona thinning improve the implantation rate of the women of advanced age in the first IVF/ICSI cycles
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Registry procedures:
- It's required to sign an informed consent form prior to the recruitment of all patients.
- Data collection and entry need double check and supervision.
The outcome measures:
the implantation rate per embryo transfer miscarriage live birth
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710003
- Recruiting
- Maternal and Children Health Care Hospital
-
Contact:
- Wenhao Shi, Master
- Phone Number: +86-029-87219120
- Email: swihao@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 46 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Age: 35y ≤age≤46y
- Basal FSH value: FSH≤10IU/L
- Day-3 embryos transferred in the fresh IVF/ICSI cycles
- the number of embryos available to be transferred on Day-3: ≥one embryo
Exclusion Criteria:
- cycles with thawed/warmed embryos biopsied for PGD/PGS.
- cycles with oocyte donation transfer.
- the maximum number of previous unsuccessful IVF attempts: ≥ 3 cycles(transfer cycles)
- any cycles with the risk of OHSS, fluid in the uterine cavity, abnormal endometrium, uterine abnormalities,pelvic inflammation, and other acute maternal problems.
- One or both spouses have an abnormal karyotype (including polymorphism)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Assisted hatching group (AH group)
The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
|
The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
|
No Intervention: Control group
The subjects are going to undergo the same procedure except for the treatment of assisted hatching.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The implantation rate
Time Frame: 30 days
|
the implantation rate per embryo in first fresh embryos transfer cycles
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The miscarriage
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Anticipated)
January 1, 2015
Study Completion (Anticipated)
July 1, 2015
Study Registration Dates
First Submitted
January 9, 2013
First Submitted That Met QC Criteria
January 9, 2013
First Posted (Estimate)
January 10, 2013
Study Record Updates
Last Update Posted (Estimate)
November 27, 2013
Last Update Submitted That Met QC Criteria
November 25, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- MCHC-2013-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Urogenital Diseases
-
Nadezhda Women's Health HospitalMedical diagnostic laboratory ImunoVitaRecruitingFemale InfertilityBulgaria
-
Istituto Clinico HumanitasCompletedFemale Infertility | SustainabilityItaly
-
Alexandria UniversityCompleted
-
Alexandria UniversityCompletedFemale InfertilityEgypt
-
Istituto Clinico HumanitasIRCCS San RaffaeleCompleted
-
Bharat Serums and Vaccines LimitedActive, not recruitingFemale InfertilityIndia
-
Northwestern UniversityCompletedMalignant Female Reproductive System NeoplasmUnited States
-
Isfahan University of Medical SciencesRecruitingInfertility | Thin Endometrium | Infertility FemaleIran, Islamic Republic of
-
Sohag UniversityNot yet recruiting
-
Instituto Valenciano de Infertilidad, IVI VALENCIARecruitingInfertility, FemaleSpain